BR112022010161A2 - Método para tratar a infecção por hiv-1 e regular a função do sistema imunológico, e, uso de um ou mais agentes antirretrovirais e n-carbamimidoil-5-(1-metilpirazol-4-il)naftaleno-2-carboxamida - Google Patents

Método para tratar a infecção por hiv-1 e regular a função do sistema imunológico, e, uso de um ou mais agentes antirretrovirais e n-carbamimidoil-5-(1-metilpirazol-4-il)naftaleno-2-carboxamida

Info

Publication number
BR112022010161A2
BR112022010161A2 BR112022010161A BR112022010161A BR112022010161A2 BR 112022010161 A2 BR112022010161 A2 BR 112022010161A2 BR 112022010161 A BR112022010161 A BR 112022010161A BR 112022010161 A BR112022010161 A BR 112022010161A BR 112022010161 A2 BR112022010161 A2 BR 112022010161A2
Authority
BR
Brazil
Prior art keywords
infection
hiv
carbamimidoyl
carboxamide
naphthalene
Prior art date
Application number
BR112022010161A
Other languages
English (en)
Inventor
Luscombe Carolyn
Ewart Gary
Miller Michelle
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904453A external-priority patent/AU2019904453A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of BR112022010161A2 publication Critical patent/BR112022010161A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

MÉTODO PARA TRATAR A INFECÇÃO POR HIV-1 E REGULAR A FUNÇÃO DO SISTEMA IMUNOLÓGICO, E, USO DE UM OU MAIS AGENTES ANTIRRETROVIRAIS E N-CARBAMIMIDOIL-5-(1- METILPIRAZOL-4-IL)NAFTALENO-2-CARBOXAMIDA. A terapia antirretroviral (TARV) atual é uma combinação de 2 a 3 agentes antirretrovirais que tem sido bem-sucedida na redução do RNA do HIV-1 no sangue e melhorou a morbidade e mortalidade da infecção pelo HIV-1 e AIDS. Apesar da TARV potente, a erradicação da infecção pelo HIV-1 permanece indefinida e há potencial para replicação persistente do vírus em reservatórios virais que podem continuar a conduzir a progressão da doença patogênica. Consequentemente, existe a necessidade de agentes que auxiliem na erradicação da infecção por HIV-1. A presente invenção se refere ao tratamento de infecção por HIV-1 pela administração de N-carbamimidoil-5-(1-metilpirazol-4-il)naftaleno-2-carboxamida em combinação com agentes antirretrovirais.
BR112022010161A 2019-11-26 2020-11-25 Método para tratar a infecção por hiv-1 e regular a função do sistema imunológico, e, uso de um ou mais agentes antirretrovirais e n-carbamimidoil-5-(1-metilpirazol-4-il)naftaleno-2-carboxamida BR112022010161A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904453A AU2019904453A0 (en) 2019-11-26 Methods of treating HIV-1 infection
AU2020902273A AU2020902273A0 (en) 2020-07-03 Methods of treating hiv-1 infection
PCT/AU2020/051273 WO2021102508A1 (en) 2019-11-26 2020-11-25 Methods of treating hiv-1 infection

Publications (1)

Publication Number Publication Date
BR112022010161A2 true BR112022010161A2 (pt) 2022-08-09

Family

ID=76128599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010161A BR112022010161A2 (pt) 2019-11-26 2020-11-25 Método para tratar a infecção por hiv-1 e regular a função do sistema imunológico, e, uso de um ou mais agentes antirretrovirais e n-carbamimidoil-5-(1-metilpirazol-4-il)naftaleno-2-carboxamida

Country Status (12)

Country Link
US (1) US20220409587A1 (pt)
EP (1) EP4065106A4 (pt)
JP (1) JP2023503903A (pt)
KR (1) KR20220104773A (pt)
CN (1) CN114980885A (pt)
AU (1) AU2020390851A1 (pt)
BR (1) BR112022010161A2 (pt)
CA (1) CA3158591A1 (pt)
IL (1) IL293160A (pt)
MX (1) MX2022006274A (pt)
WO (1) WO2021102508A1 (pt)
ZA (1) ZA202206123B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092180A1 (en) * 2021-11-24 2023-06-01 Biotron Limited Methods of treating sars-cov-2 infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140072101A (ko) * 2005-06-24 2014-06-12 바이오트론 리미티드 항바이러스 화합물 및 방법
WO2008096369A2 (en) * 2007-02-05 2008-08-14 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection

Also Published As

Publication number Publication date
CN114980885A (zh) 2022-08-30
EP4065106A4 (en) 2023-12-20
EP4065106A1 (en) 2022-10-05
WO2021102508A1 (en) 2021-06-03
IL293160A (en) 2022-07-01
KR20220104773A (ko) 2022-07-26
MX2022006274A (es) 2022-10-13
US20220409587A1 (en) 2022-12-29
JP2023503903A (ja) 2023-02-01
AU2020390851A1 (en) 2022-06-09
ZA202206123B (en) 2023-11-29
CA3158591A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
BR112018010505A2 (pt) mistura de oligossacarídeos de leite humano (hmos)
BR112022017243A2 (pt) Lactoferrina para uso oral com ação antiviral
CL2022002030A1 (es) Sars-cov-2 desoptimizados y métodos y usos de los mismos
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
MA40769B1 (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
BR112021019931A2 (pt) Parasiticidas isoxazolina sistêmicos para tratamento ou profilaxia de doença transmitida por vetor e viral
PA8744101A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
BR112019005205A2 (pt) composto de di-hidropirimidina e método de preparação e uso do mesmo
BR112022010161A2 (pt) Método para tratar a infecção por hiv-1 e regular a função do sistema imunológico, e, uso de um ou mais agentes antirretrovirais e n-carbamimidoil-5-(1-metilpirazol-4-il)naftaleno-2-carboxamida
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
BR112022010425A2 (pt) Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
MX2021010834A (es) Compuesto y metodo para la prevencion de transmision del virus de influenza.
MX2022013722A (es) Cisteamina para el tratamiento de infección por sars-cov-2.
BR112022010340A2 (pt) Composições farmacêuticas
BR112022019357A2 (pt) Medicamento/agente para o tratamento de coronavírus, infecções retrovirais e hepatite c
BR112022009421A2 (pt) Regimes de dosagem para vacinas
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
BR112022022635A2 (pt) Parapoxvírus para condicionamento e tratamento de infeções por coronavírus
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
MX2022013814A (es) Tratamiento de infecciones virales.
BR112022003126A2 (pt) Conjugado terapêutico